Tandem Diabetes Care, Inc.

TNDM

US8753722037

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 02:30:00 24/01/2026 am IST			5-day change	1st Jan Change
19.90 ^USD	-3.35%		-1.29%	-9.46%

18/12	Tandem Diabetes Care, Inc. Announces Availability of the Tandem T:Slim Mobile Application for Android and iOS Users in Canada	CI
18/12	Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating	MT

Tandem Diabetes Care, DexCom Say Health Canada Authorizes T:Slim X2 Insulin Pump

Published on 07/29/2024 at 08:41 pm IST - Modified on 07/29/2024 at 08:42 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Tandem Diabetes Care, Inc.

18/12	Tandem Diabetes Care, Inc. Announces Availability of the Tandem T:Slim Mobile Application for Android and iOS Users in Canada	CI
18/12	Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating	MT
17/12	RBC Adjusts Price Target on Tandem Diabetes Care to $30 From $25, Maintains Outperform Rating	MT
17/12	North American Morning Briefing : Stock Futures, Oil Rise After Venezuela Blockade -2-	DJ
17/12	Tandem Diabetes Care Shares Rise After Baird Upgrade	MT
16/12	Baird Upgrades Tandem Diabetes Care to Outperform From Neutral, Adjusts PT to $30 From $18	MT
12/11	Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025	CI
10/11	Tandem Says FDA Clears Tandem Mobi App Android Version	MT
10/11	Tandem Diabetes Care, Inc. Receives FDA Clearance for Use with Android Smartphones	CI
07/11	Tandem Diabetes Care, Inc., Q3 2025 Earnings Call, Nov 06, 2025
07/11	Tandem Diabetes Q3 sales rise 2%, gross margin improves	RE
07/11	Earnings Flash (TNDM) Tandem Diabetes Care, Inc. Reports Q3 Revenue $249.3M, vs. FactSet Est of $235.8M	MT
07/11	Tandem Diabetes Care, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/11	Tandem Diabetes Care, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025	CI
01/25/01	Tandem Diabetes Care announces upcoming conference presentations	RE
29/25/29	Tandem Diabetes Care, Inc. Announces Tandem Diabetes Care, Inc. Insulin Pump Now Available with Abbott's Freestyle Libre 3 Plus Sensor in the United States	CI
29/25/29	Tslim X2(TM) insulin pump now available with Abbott's Freestyle Libre® 3 Plus sensor in the United States	RE
29/25/29	Tandem Diabetes Care, Inc.'s t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-Rapid Acting Insulin in the United States	CI
16/25/16	Tandem Diabetes Care, Inc. Announces Publication Showing Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels	CI
16/25/16	Tandem study- adults with type 2 diabetes benefit from automated insulin delivery, regardless of C-peptide levels	RE
16/25/16	Fda Tandem Diabetes Care Issues Correction For Certain TSlim X2 Insulin Pumps	RE
10/25/10	Tandem Diabetes Care, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 09:15 AM
08/25/08	Oppenheimer Adjusts Tandem Diabetes Care Price Target to $22 From $44, Maintains Outperform Rating	MT
04/25/04	Tandem Diabetes Care Says Mobile App Approved by Health Canada	MT
04/25/04	Brian Hansen to Join Senseonics Holdings, Inc. as Chief Commercial Officer, Effective January 1, 2026	CI

Chart Tandem Diabetes Care, Inc.

Duration

Period

TNDM: Dynamic Chart

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.

Employees

2,650

Sector

Medical Equipment, Supplies & Distribution

Calendar

20/02 - Q4 2025 Earnings Release

More about the company